Patients with advanced pancreatic cancer are needed for a study to research an experimental cellular therapy.

IRB/UVA Tracking #
19236
Principal Investigator
Tri M Le
Contact
Ioannis Vassalos
Contact Phone
434.924.9496
Official Trial Title
Phase Ib/II Treatment of Advanced Pancreatic Cancer with anti-CD3 x anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have advanced pancreatic cancer. The purpose of this study to evaluate an experimental drug (EGFR-BATs) in patients with advanced pancreatic cancer. The experimental drug dose, safety, and the effects of the drug will be evaluated for this study.

Participation is approximately 15 study visits over 8 months. This includes a screening period, leukapheresis procedure, 1-3 weeks of chemotherapy, 4 weeks of study drug treatment and possibly longer, a phone call to see how you are doing, and 4 additional clinic visits. Study specific tests that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03269526

Compensation

No Compensation; Reimbursement: You may stay in hotel accommodations arranged by the study team if you live over 40 minutes away.